Introduction
DNA inoculation represents a novel approach in vaccine and active-specific immunotherapy. Studies have shown that the immune responses induced by DNA vaccination are protective against various types of infectious diseases and tumors. [1] [2] [3] [4] [5] The direct injection of gene expression cassettes into host can transform cells in vivo into factories producing the introduced gene products similar to virus infected cells. Expression of these delivered genes, particularly if foreign to the normal cell transfected, can lead to induction of antigen-specific immunological responses. This is a novel approach of presenting tumor antigens on normal cells to induce tumor protective immunity. Generation of potent effector immune responses to tumorassociated antigens is often a difficult task. Tumor antigen DNA immunization may overcome the problems of traditional antigen-based approaches and provide safe, effective prophylactic and therapeutic vaccines. Similar to live attenuated vaccines, the antigens are synthesized within the host cells by DNA immunization. The transfected cells display specific peptide sequences of the antigens on their cell surfaces by major histocompatibility antigens class I (MHC I), as do virally infected cells. Peptides presented by MHC I molecules are recognized by T cells such as cytotoxic T cells (CTL). CTLs specific to tumor antigens are known to play a role in tumor control and destruction.
Human melanoma-associated antigen gp100 is a melanocyte differentiation antigen specifically recognized by HLA-A restricted T cells derived from melanoma patients, and has been suggested to play a role in tumor regression. 6 The antigen has been shown to be highly immunogenic and an important target for active-specific immunotherapy in humans. 7, 8 The human gp100 gene, which has 75.5% identity to mouse gp100 gene cloned from the B16 cDNA, 9 can induce some level of protective tumor immunity in C57BL/6 mice after immunization by adenovirus-mediated gene transfer.
7 Gp100 is well expressed in both murine and human melanomas. 9, 10 Studies have reported injection of plasmid DNA containing tumor-associated antigens to induce tumor immunity. A well-known problem with naked DNA alone injection is its poor transfection and overall long-term efficacy. We developed a more practical approach using a novel viral vector-based delivery system for cancer vaccination using tumor antigen DNA inserted in a plasmid and delivered by HVJ-liposomes into skeletal muscles of mice.
11 DNA immunization intramuscularly has been shown to be an effective route for getting good transfection of cells as well as activating antigen-specific immune responses.
The hemagglutinating virus of Japan (HVJ)-liposome gene transfer method enables us to deliver contents such as nucleic acids and proteins directly and efficiently into host cells in vivo by means of the virus cell fusion machinery. 11 Recently, we demonstrated that repetitive gene transfer can be achieved by HVJ-liposome vector system without side-effects or neutralization of the delivery system. 12 In our previous studies we demonstrated that when pcDNA3 plasmid containing the human tumor antigen genes MAGE-1 and MAGE-3 were encapsulated in HVJ-liposomes and injected into mice intramuscularly, there were no side-effects and there was highly efficient transfection of muscle cells for several weeks. 11 Recently, we improved the HVJ-liposome system for more efficient gene delivery by changing the lipid components of the liposomes, and developed a novel HVJ-AVE (artificial viral envelope) liposome which increased gene expression in mouse skeletal muscle and liver five to 10 times higher compared with conventional HVJliposomes. 13 In this study, we assessed the fusigenic HVJ-liposome system to transfer the gene encoding human gp100 antigen into mice intramuscularly. Both anti-gp100 antibody and CTL responses were induced in the immunized mice. When challenged with B16 melanoma cells, the gp100 DNA immunized mice displayed a delayed disease-free interval before tumor development and had a significantly prolonged survival period, in comparison to the controls that were treated with HVJ-liposomes without DNA.
Results
Detection of gene expression in muscle by Northern blotting To test in vivo expression of gp100 DNA, pSH40 plasmid containing human gp100 cDNA encapsulated in fusigenic HVJ-AVE liposomes was injected into the hind quadriceps of mice. Three and 10 days after injection, the mice were killed and the injection site muscle tissues were isolated. The control muscle tissue was from mice which had not been immunized. Total RNA was prepared from each muscle tissue specimen and tested by Northern blotting using a 32 P-labeled gp100 cDNA probe. The results demonstrated that the gene was highly expressed in muscle tissues 1 day after injection (Figure 1, lane 2) . Then, the transcript gradually decreased and on day 14 after the transfer it was faint but still detectable ( Figure 1, lanes  3-5) . The half-life of human gp100 in muscle was about 3 days. By naked DNA injection no expression was observed after 10 days (data not shown). No gp100 expression was detected in the control muscle injected with HVJ liposomes containing pcDNA3 ( Figure 1, lane  1) . The results confirmed that gp100 DNA was transfected into and expressed in muscle cells.
Immunization with gp100 DNA-HVJ-liposome Mice (n = 6) were immunized with gp100 DNA-HVJ-AVE liposomes intramuscularly. A booster immunization was performed at the same sites 2 weeks after the first immunization. The control group was immunized with HVJ-liposomes containing pcDNA3 without gp100 cDNA. Four weeks after the first immunization, the mice were challenged by inoculation of 2.5 × 10 3 B16 tumor cells in foot pads. About 3 weeks after B16 cell challenge, tumors began to develop. The results demonstrated that tumor development was delayed in the gp100 DNA immunized mice compared with the controls (data not shown). Furthermore, gp100 DNA vaccination led to prolonged survival of the mice (Figure 2a ). The effect of immunization on mouse survival was significant (P Ͻ 0.05). We also performed the gp100 immunization using female C57BL/6 mice. The mice immunized with gp100 died on days 65, 65, 75, 88, 120 and 130, whereas by the injection with pcDNA3 mice died on days 50, 54, 58, 60, 69, 70 and 80, which was also significant (P Ͻ 0.05).
By gp100 naked cDNA immunization, the mice (n = 6) died on days 56, 60, 62, 70, 75 and 105, whereas by pcDNA3 injection, the mice died on days 44, 55, 59, 68, 72 and 82 (Figure 2b ). These were not significant (P Ͻ 0.10).
Detection of anti-gp100 antibody Mice were immunized with gp100 DNA-HVJ-AVE liposomes in week 0, and a booster immunization was performed on day 27 after the first immunization. Mouse sera were collected and tested for the anti-gp100 specific antibody by immunoprecipitation with gp100 protein. Gp100 protein was in vitro translated and labeled with 35 S methionine from plasmid pSH40, immunoprecipitated, subjected to SDS-PAGE, and measured by an image analyzer. A band at approximately 82 kDa was seen after immunoprecipitation with sera from gp100 DNA immunized mice ( Figure 3 , lane 2). No band was observed after immunoprecipitation with the sera from the control HVJliposome alone immunized mice ( Figure 3, lane 3 ). The results demonstrate that anti-gp100 antibody was induced after vaccination of mice with gp100 DNA. The human gp100 protein glycosylated is approximately 95 kDa. 7 The in vitro translated gp100 protein showed a band of approximately 82 kDa in size.
Cell-mediated immune response
To test whether anti-B16 CTL were induced in vivo by gp100 DNA vaccination before tumor development, spleen cells were dissected out from the immunized mice 3 weeks after the second immunization. The splenocytes were re-stimulated in vitro for 5 days with mitomycin Ctreated B16 cells and then mixed with 3 × 10 3 B16 cells (targets) at different effector to target ratios. After 4 h of co-culturing at 37°C, 5% CO 2 , the percentage of specific cytotoxity was determined by measuring the lactate dehydrogenase (LDH) activity released from the lysed target cells into the supernatant. CTL response to trinitrophenyl (TNP) was used as a positive control, and TNPmodified lymphocytes could lyse TNP-pulsed B16 cells but not normal B16 cells (Figure 4a) . The results demonstrated that CTL response to B16 cells induced after gp100 DNA immunization could lyse B16 tumor cells in vitro. In contrast, similarly restimulated splenocytes from empty HVJ-AVE liposome immunized mice did not demonstrate significant CTL activity against B16 tumor cells (Figure 4b ). Using a random coefficient model, the response of CTL in the vaccine group was significantly (P Ͻ 0.005) higher than control mice CTL response.
Discussion
Several reports have demonstrated that DNA vaccination can trigger antigen-specific humoral and cell-mediated protective immunity against infectious diseases and cancers. The relatively short development time, ease of large-scale production, and low development, manufacturing costs combined with immunological effectiveness of DNA immunization technology indicates its potential towards a new generation of effective vaccines in the near future.
The present study used a novel fusigenic viral liposome gene transfer system for vaccination. The HVJ-liposomes can efficiently deliver encapsulated exogenous molecules directly into cells by means of HVJ-mediated membrane fusion. [14] [15] [16] [17] Using the HVJ-liposome complexes, plasmid DNA and/or oligodeoxynucleotides (ODNs) have been efficiently delivered into a variety of organs and tissues without significant toxicity or inflammation. 18, 19 The efficacy and consistent in vivo transfection of the HVJ-liposome system has been well demonstrated in multiple model systems. This delivery system allows for larger genes to be transferred and for several genes to be delivered together.
Our previous study showed that immunization of mice intramuscularly with the human antigen genes MAGE-1 and MAGE-3 by HVJ-AVE liposomes induced antigenspecific antibodies. In this study, we utilized the fusigenic viral-liposome system to transfer the human gp100 antigen gene into mice intramuscularly. The results showed that both anti-gp100-specific antibody and CTL response to B16 melanoma were induced in the immunized mice. When challenged with B16 melanoma tumor cells, the gp100 DNA immunized mice displayed delayed tumor development and prolonged survival compared with control mice. These results demonstrate that limited vaccination of naive mice with human gp100 DNA by the HVJ-liposome gene transfer system can induce protective tumor immunity in mice. Compared with the results by naked DNA immunization, HVJ-liposomes were much more effective in inducing tumor immunity. However, all of the immunized mice eventually died under this protocol. This suggests that although gp100 DNA vaccination can induce protective immunity against melanoma with the immunization schedule, the immune responses are not potent enough to control tumor progression completely or to eliminate melanoma tumors. Future studies will involve examining more elaborate immunization schedules to enhance responses. In human melanoma studies it has been observed that a single tumor antigen is not uniformly or highly expressed by all melanoma cells which may be a limiting factor in the vaccine effectiveness. 20 Human gp100 DNA is not totally homologous to mouse melanoma gp100 and may thus limit protective immunity against B16 melanoma. Human gp100 was used in this mouse melanoma system as a pre-clinical model for melanoma vaccine. Previous studies have demonstrated that murine gp100 antigen immunization was not protective against B16 melanoma.
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Cancer vaccination may have more prophylactic benefits such as after the surgical removal of melanoma or when tumors are in the early stages of progression (subclinical disease). 21 In general, melanoma patients with AJCC II (local) or III (local regional) level disease will undergo surgical treatment to be disease free. However, the major problem that arises is disease recurrence and who will recur. This is an ideal target area for vaccination to promote immunity and control/prevent disease relapse. Vaccination of the host (with established larger tumors) may have limited therapeutic benefit overall. The mouse melanoma pre-clinical model system presented with gp100 demonstrates its potential application. Previously, we demonstrated induction of MAGE-1 and MAGE-3 immune responses after DNA-HVJ-liposome immunization. 13 Unfortunately, mouse melanomas do not express MAGE family genes. Thus it is difficult to demonstrate protective tumor immunity. Since gp100 is well expressed in human melanomas and very immunogenic, it is an excellent target for DNA vaccines. The efficacy of the HVJ-liposome plasmid DNA vector will provide a mechanism for consistent transfection and immunization without potential side-effects.
Materials and methods

Vector construction
The cDNA of gp100 (1899 base pair) full-length sequence which encodes for 633 amino acids was amplified by RT-PCR from total RNA isolated from the established melanoma cell line M12 at John Wayne Cancer Institute. The 5Ј primer region contained a SacI site and the 3Ј primer contained an XhoI site for subcloning PCR product into a modified GST-fusion expression vector pGEX-2T (Pharmacia, Piscataway, NJ, USA) as previously described. 8 The cDNA of gp100 as a EcoRI-XhoI fragment derived from expression vector was cloned into respective sites of pcDNA3 (Invitrogen, La Jolla, CA, USA) to construct plasmid pSH40.
Mouse strain and cell culture
The mice used in the experiments were male, 6 weeks old, of the C57BL/6 strain. The B16-F1 melanoma tumor cell line which is syngeneic to C57BL/6 mice and has H2 b antigen 22 was maintained in Dulbecco's modified Eagle's medium (DMEM) containing 4.5 g/l glucose with 10% fetal bovine serum (FBS), penicillin (100 U/ml) and streptomycin (1 mg/ml) at 37°C in a humidified atmosphere of 5% CO 2 .
Preparation of DNA-HVJ-AVE liposomes Plasmid DNA was prepared by Qiagen (Hilden, Germany) and then resuspended in 10 mm Tris-HCl, pH 8.0, 0.1 mm EDTA. DNA-HVJ-AVE liposomes were prepared as described. 13 Briefly, 200 g plasmid DNA in 200 l of TE (200 l TE alone for control empty liposomes) was added to a tube containing dried lipid, shaken vigorously and sonicated to form liposomes. Purified hemagglutinating virus of Japan (HVJ) was inactivated by UV radiation (198 mJ/cm 2 ) before use. One milliliter of HVJ solution was combined with the liposomes, incubated on ice for 10 min and then at 37°C with shaking for 1 h to form fusigenic HVJ-AVE liposomes. The DNA-liposome complexes were purified by centrifugation in a 30% sucrose solution and resuspended in 300 l of balanced salt solution (BSS; 137 mm NaCl, 5.4 mm KCl, 10 mm TrisHCl pH 7.6).
Gp100 DNA immunization and B16 cell challenge Mice (n = 6) were immunized with 100 l of the DNA-HVJ-AVE liposome solution by injection into the quadriceps of the hind leg at three sites. Trapping efficiency of DNA by HVJ-liposomes was 15-20%. The dose of gp100 DNA injected was 10-13.3 g per mouse and 3.3-4.4 g per injection site.
Mice (n = 6) were also immunized with naked gp100 expression vector, pSH40. Fifty micrograms of each plasmid (about four-fold the amount of DNA delivered by HVJ-liposomes) were injected into the quadriceps of C57BL/6 male mice at three different sites. As a negative control, the same amount of pcDNA3 was injected. A booster injection with the same amount of DNA-HVJ-AVE liposomes or naked DNA was given 2 weeks later at the same site. Two weeks after the boost, 2.5 × 10 3 B16 cells in 15 l of phosphate-buffered saline (PBS; 137 mm NaCl, 3 mm KCl, 8 mm Na 2 HPO 4 , 1 mm KH 2 PO 4 , pH 7.4) was injected intradermally into the hind foot pad. Before tumor challenge, we determined the minimal dose of B16 cells which consistently produced tumors in 3 weeks in all the mice injected. The mice were monitored every 2 days for tumor development.
Northern blotting
Total RNA was prepared from the muscle tissues using Isogen (Nippon Gene, Tokyo, Japan) following manufacturer's instructions. Twenty micrograms of RNA sample were electrophoresed in a 1% agarose formaldehyde gel and transferred on to a nylon membrane (Hybond-N+, Amersham, Buckinghamshire, UK). The membrane was dried at 80°C for 20 min and pre-hybridized in 25 ml of 5 × Denhardts, 5 × SSC, 50% formamide, 0.5% SDS and 800 g of denatured salmon testis DNA at 42°C for 1.5 h. A 32 P-labeled gp100 cDNA probe was added to the solution and hybridized at 42°C overnight. A 32 P-labeled glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Clontech, Palo Alto, CA, USA) probe was used as an internal control. The membrane was washed, dried, and then exposed to a radiographic film.
In vitro translation of gp100 protein Human gp100 protein was in vitro translated using the TNT Coupled Reticulocyte Lysate System (Madison, Promega, WI, USA). Briefly, 1 g of pSH40 plasmid DNA was mixed with 25 l of TNT rabbit reticulocyte lysate, 2 l of TNT reaction buffer, 1 l of TNT RNA polymerase, 1 l of amino acid mixture minus methionine, 4 l of 35 S methionine at 10 mCi/ml, 1 l of RNasin ribonulease inhibitor (10 U/l), and nuclease-free H 2 O to a final volume of 50 l. The mixture was then incubated at 30°C for 60 min.
Immunoprecipitation Twenty-five microliters of in vitro translated gp100 protein were mixed with 40 l of 50% protein G-Sepharose CL6B (Pharmacia, Piscataway, NJ, USA), rotated at 4°C for 1 h and centrifuged at 10 500 g for 5 min to remove the nonspecific binding proteins. The supernatant was transferred to a microcentrifuge tube and mixed with 100 l of the anti-serum. The mixture was rotated at 4°C for 3 h, then centrifuged at 10 500 g for 15 min. Forty-five microliters of 50% protein G-Sepharose CL6B were added and rotated at 4°C overnight. The mixture was centrifuged at 6000 g for 2 min and the supernatant removed. The pellet was washed three times with 1 ml of TBS-T (50 mm Tris, pH 7.5, 150 mm NaCl, 0.05% Tween-20) by rotation at 4°C for 10 min and resuspended in 60 l of Laemmli's sample buffer. The sample was vortexed, boiled at 95°C for 5 min, and centrifuged at 6000 g for 2 min. The supernatant was applied to a 8% polyacrylamide gel for SDS-PAGE. After SDS-PAGE the gel was fixed with 50% methanol and 7% acetic acid at room temperature for 30 min, rinsed twice with distilled water, subjected to fluorography in 0.5 m sodium-salicylate at room temperature for 30 min and dried at 80°C for 2 h. The intensity of the signals was measured by an image analyzer (BASS 2000; Fuji, Tokyo, Japan).
CTL assay
The CTL assay against B16-F1 cells was carried out by a modified method described previously with splenocytes.
12 Ggp100 was not used for CTL assay because of difficulties in purification. After immunization, effector cells were collected from mouse spleen in 15 ml of RPMI with 10% fetal calf serum (FCS) in a 40 ml conical tube and centrifuged at 1200 r.p.m. for 10 min. Red blood cells were removed by resuspending the cells in 4 ml of a lysing buffer (0.1 m NH 4 Cl, 1.0 m KHCO 3 , 0.1 mm Na 2 EDTA, pH 7.3). The tube was kept at room temperature for 5 min and then diluted with RPMI 1640 medium containing 10% FBS and centrifuged at 200 g for 10 min. The splenocytes were washed twice by adding 30 ml of sensitization medium (SM) consisting of RPMI 1640 medium with 10% FBS containing 1 mm sodium pyruvate, 1 × non-essential amino acids, and 50 m 2-␤-mercaptoethanol and centrifuged at 200 g for 10 min. Effector cells were restimulated by mixing 3 × 10 7 splenocytes with 2 × 10 6 B16 cells in 12 ml of SM and co-cultured at 37°C, 5% CO 2 . Before mixing, the B16 cells were treated with mitomycin C (25 g/ml) at 37°C, 5% CO 2 for 30 min and then washed eight times with PBS. After 5 days of in vitro restimulation, the unattached cells were collected and purified with Ficoll-Paque solution. The effector cells were mixed with 3 × 10 3 B16 target cells in 200 l of RPMI 1640 medium with 1% FBS in a flat-bottom 96-well plate in triplicate at different ratios, and cultured at 37°C, 5% CO 2 for 4 h. The plate was centrifuged at 250 g for 5 min, 100 l of culture supernatant was removed and LDH activity was determined using a cytotoxity detection kit (LDH; Boehringer Mannheim, Indianapolis, IN, USA) as described by the manufacturer. The target cells cultured in RPMI 1640 plus 1% FBS containing 0.1% Triton X-100 served as the high control and the cells cultured in RPMI 1640 plus 1% FBS alone served as the low control. The percentage of specific lysis was calculated by the following equation: specific lysis % = [(effector-target cell mix − effector cell control) − low control] × 100 high control − low control As a positive control for CTL response, specific lysis by TNP-injected splenocytes was assessed in TNP-modified B16 cells. 23, 24 Statistical analysis Analysis of variance with two sample t test was used to determine the significance of differences in negative controls. P Ͻ 0.05 was considered significant.
